Your browser doesn't support javascript.
loading
Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors.
Krokhotin, Andrey; Du, Hongwei; Hirabayashi, Koichi; Popov, Konstantin; Kurokawa, Tomohiro; Wan, Xinhui; Ferrone, Soldano; Dotti, Gianpietro; Dokholyan, Nikolay V.
Affiliation
  • Krokhotin A; Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Du H; Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Hirabayashi K; Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Popov K; Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Kurokawa T; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Wan X; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Ferrone S; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Dotti G; Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Dokholyan NV; Department of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Mol Ther Oncolytics ; 15: 30-37, 2019 Dec 20.
Article in En | MEDLINE | ID: mdl-31650023
Chimeric antigen receptor (CAR)-T cell-based immunotherapy of malignant disease relies on the specificity and association constant of single-chain variable fragments (scFvs). The latter are synthesized from parent antibodies by fusing their light (VL) and heavy (VH)-chain variable domains into a single chain using a flexible linker peptide. The fusion of VL and VH domains can distort their relative orientation, thereby compromising specificity and association constant of scFv, and reducing the lytic efficacy of CAR-T cells. Here, we circumvent the complications of domains' fusion by designing scFv mutants that stabilize interaction between scFv and its target, thereby rescuing scFv efficacy. We employ an iterative approach, based on structural modeling and mutagenesis driven by computational protein design. To demonstrate the power of this approach, we use the scFv derived from an antibody specific to a human leukocyte antigen A2 (HLA-A2)-HER2-derived peptide complex. Whereas the parental antibody is highly specific to its target, the scFv showed reduced specificity. Using our approach, we design mutations into scFvs that restore specificity of the original antibody.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Mol Ther Oncolytics Year: 2019 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Mol Ther Oncolytics Year: 2019 Document type: Article Affiliation country: Country of publication: